ABSTRACT Studies presented here demonstrate that heparin inhibits EcoR I endonuclease cleavage of DNA whereas related proteoglycans show no effect. The inhibition occurs at particular EcoR I sites that are near or overlap with palindromic sequences in the murine X5 and Lyt-2
INTRODUCTION
Heparin is a proteoglycan composed of sulfated polysaccharides attached to a core protein (1) (2) (3) . Commercial heparin, which mainly contains the sulfated polysaccharide chains without the core protein, binds to a variety of positively charged molecules, including endonucleases, and is often used for chromatographic purification of EcoR I endonuclease and other proteins (4) (5) (6) (7) . It is also used routinely as an anticoagulant when isolating cells from blood.
Heparin is widely distributed in animal organs and is particularly abundant in mouse peritoneal mast cells (3, 9-1 1). In its natural form, it is similar to DNA in that it is a heterogeneous mixture of highly negatively charged macromolecules that are resistant to proteinase treatment. Thus, it often co-isolates with DNA and tends to contaminate DNA preparations from sources rich in heparin-containing cells such as the mouse peritoneum (3, 9, 12) . In addition, it tends to contaminate DNA isolated from cells that have been harvested from blood to which heparin has been added as an anticoagulant (even though commercial heparin molecules are smaller in size) (8) .
Studies presented here underscore the importance of such contamination by showing that the restriction endonuclease digestion of DNA at certain sites is inhibited by heparin. Southern analyses of EcoR I digests of spleen DNA using X5 genomic or Lyt-2 cDNA probes yield bands whose sizes are predicted by the restriction sites in genomic maps. In contrast, Southern analyses of peritoneal DNA digests using the same probes yield additional bands that are larger than those predicted by the genomic maps. These larger bands are due to sufficient amounts of heparin co-purifying with DNA and heparin inhibiting EcoR I cleavage of DNA at EcoR I sites that are near or overlap with palindromic sequences. Thus, heparin co-purified with DNA may introduce artifacts in restriction fragment length analyses. Nevertheless, addition of appropriate amounts of heparin into EcoR I digestion mixture can produce controlled, partial digests of DNA that contains inhibitable sites. Isolation of genomic DNA Genomic DNA was isolated as described (13 Fig. 2A) . Thus, heparin, but not other related proteoglycans, inhibits EcoR I endonuclease cleavage of DNA at a particular EcoR I site in the X5 gene.
MATERIALS AND METHODS

Materials
Based on the X5 genomic map, the EcoR I site inhibited is the one in exon III ( Fig. iB) (14) . When this site is blocked, a 1.8 kb fragment instead of the expected 1.4 kb fragment is generated. thus its digests give rise to two hybridizing bands. Since the second Rsa I site and the second and the third EcoR V sites are not defined in the known DNA sequences, the fragment sizes of Rsa I and EcoR V digests can not be predicted. However, both spleen DNA and peritoneal DNA digests give rise to identical band pattern, suggesting that the digestion is not inhibited by heparin as determined with X5 probe. The weak bands at about 9 kb are generated from cross-hybridization to the immunoglobulin CKl sequence. (Fig. 1A, lane 10) . In fact, the 1.8 kb band consistently predominates in peritoneal DNA digests, regardless of the age or sex of the peritoneal cell donors (BALB/c, C57BL/6 and CBA/Ca). In contrast, the 1.8 kb band is never seen with spleen DNA from any of these mice unless heparin is added to the digestion mixture. The generation of the 1.8 kb fragment in EcoR I digestion of peritoneal DNA is clearly due to the presence of endogenouslyderived heparin. Treating peritoneal DNA with heparinase before A digestion yields only the 1.4 kb fragment whereas treating this DNA with RNase A or proteinase K yields both the 1.4 kb and the 1.8 kb fragments ( Fig. 2A and B) . DNase I treatment degrades all DNA, however, the inhibitory activity remains (Fig. 2B) . Furthermore, heparin co-purified with peritoneal DNA behaves identically to exogenous heparin. It inhibits EcoR I digestion of DNA at the EcoR I site in the X5 exon HI but not at other nearby sites. Nevertheless, the co-purified heparin neither grossly alters X5 DNA nor is simply bound to DNA at the EcoR I site whose digestion it blocks, since digestion of peritoneal DNA by EcoR V or Rsa I is not inhibited (Fig. IC) . These EcoR V and Rsa I sites are in the X5 exon Ill, and the latter is only seven nucleotides away from the inhibited EcoR I site ( Fig. 1 and 4) .
The amount of heparin that co-purifies with peritoneal DNA is greater than the amount necessary to block digestion of this DNA. The co-purified heparin also blocks digestion of spleen DNA that is added to the peritoneal DNA prior to digestion. As indicated above, digestion of peritoneal DNA mainly yields the (Fig. 1, lanes 11 to 14) , or spleen and peritoneal cells are mixed at different proportions prior to DNA isolation and digestion (Fig. 2C) , the yield of the 1.8 kb fragment is substantially higher than the contribution expected from peritoneal DNA alone. The yield of the 1.4 kb fragment is substantially lower than the complete EcoR I digestion of spleen DNA. These findings show that the co-purified heparin in peritoneal DNA preparation is free and able to complex with EcoR I enzyme and/or EcoR I-DNA complex during digestion. The commercial heparin used in our experiments is a 13,000 to 15,000 dalton polysaccharide fraction without the core protein as compared to intact heparin of 750,000 daltons in the mouse (3, 4) . As we have shown, commercial heparin and the native heparin from mouse peritoneal mast cells have the same inhibitory activity. Thus, heparin inhibition of EcoR I digestion at certain sites is mediated by the polysaccharide chains of the heparin molecule. These polysaccharide chains are known to bind to EcoR I endonuclease since this enzyme is normally purified by heparin column chromatography (7) . Therefore, it is likely that heparin and EcoR I are complexed in the digestion mixture and that this complex is specifically incapable of digesting certain EcoR I sites.
Palindromes probably define the heparin-inhibitable EcoR I sites We used a series of DNA probes derived from P1450, Ly-1, Cxl, DHFR, and Ii genes to search for other EcoR I sites whose digestion might be blocked by heparin. Among these genes, only the EcoR I site in exon I of the Lyt-2 gene is affected resulting in the generation of a 2.9 kb fragment instead of a 2.3 kb fragment expected from complete EcoR I digestion (Fig. 3) (Fig. 4) (14, 16) (8) .
The alterations of EcoR I enzymatic activity in the presence of heparin are consistent with other findings demonstrating that EcoR I cleavage rates are influenced by the DNA sequences that flank the EcoR I site. For example, dA dT base pairs next to the site appear to enhance the rate of cleavage while adjacent dG-dC base pairs slow down the cleavage rate (17) (18) (19) .
Similarly, we find that palindromic sequences near an EcoR I site appear to interfere with digestion of this site when the enzyme is complexed to heparin, either because the complexed enzyme has difficulty recognizing an EcoR I site located near a palindrome or because the presence of the palindrome sharply decreases the rate of cleavage at such a site. In any event, the formation of the heparin-enzyme complex further restricts the specificity of EcoR I endonuclease such that certain sites, particularly those located near palindromes, are no longer digestible by the enzyme.
Since this restricted EcoR I specificity can be achieved by addition of appropriate amounts of heparin to a digestion mixture, the complexed enzyme can be used to produce controlled, partial digests of DNA that contains inhibitable sites. Thus although the introduction of heparin into EcoR I digests should usually be avoided (to prevent artifacts), there are certain circumstances where the addition of heparin to the digestion mixture can prove valuable.
